IOL

Sam Garg, MD, discussed his paper on the 36-month outcomes for the Juvene modular intraocular lens at the 2023 ASCRS annual meeting in San Diego.

Daniel Chang, MD, discussed his paper on a study comparing TECNIS Symfony OptiBlue IOL with the TECNIS Symfony Legacy IOL at the 2023 ASCRS annual meeting in San Diego.

Rob Thornhill, CEO of Centricity Vision, discussed the FDA clearing of ZeptoLink at the 2023 ASCRS annual meeting in San Diego.

Ophthalmology Times© met with Eva Liang at the 2023 ASCRS annual meeting in San Diego where she presented data on outcomes of the Rasch-scaled Catquest-9SF questionnaire before and after implantation of the enVista toric lens.

Ophthalmology Times© caught up with Alice Epitropoulos at the 2023 ASCRS annual meeting in San Diego. Among her presentations at the event, she shared data regarding the visual and refractive outcomes of aberration-free monofocal hydrophobic toric IOLs.

Alcon presented details from a new study at the American Society of Cataract and Refractive Surgery’s annual meeting taking place in San Diego, California. The investigator-initiated study led by J. Morgan Micheletti, MD, demonstrated that Clareon and Eyhance monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Ophthalmology Times© met with Robert Lin, MD at the 2023 ASCRS meeting in San Diego, where he shared his experience using ICLs in his practice and the advancements that help make these devices the right choice for patients.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Erisa Yotsukura, MD, PhD, offered details of a study examining an IOL that transmits violet light and a second option that does not, and they believe this can affect differences in the choroidal thickness after cataract surgery.

According to the company, outcomes show the potential for its modular, shape changing lens system.

The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimized visual outcomes.

The study compared 126 IOL injectors of 13 IOL injector systems regarding the manufacturers’ recommended preoperative incision sizes to evaluate the intraoperative incision enlargement and postoperative incision sizes.

A comparison of Hoya Vivinex and Alcon AcrySof lenses evaluated the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed.

Blake K Williamson MD, MPH, MS, discussed initial impressions of a female patient with high myopia and astigmatism who is an ideal candidate for phakic IOL implant.

Blake K Williamson MD, MPH, MS, reviews a case of a 39-year-old female with high myopia and astigmatism seeking surgical refractive correction.

Blake K Williamson MD, MPH, MS, evaluates surgical correction options for a patient with low myopia and astigmatism and describes how phakic intraocular lens (IOL) implant can be a preferable option even in low myopia.

Blake K Williamson MD, MPH, MS, presents a case of a 36-year-old male patient with low myopia and astigmatism seeking surgical refractive correction.

Survey participants were asked to enumerate the signs, symptoms, and complaints, the preoperative visual acuities; complications requiring removal or exchange; and secondary interventions.

The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

According to physicians, patients who do not undergo second procedure are more likely to develop glaucoma.

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

The SBL-3 ClearView clinical study, an FDA investigational device exemption clinical trial conducted at 18 sites across the US, is a prospective, subject-masked, randomized, two-arm study.

The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

A recent study showed that only 6% of practicing ophthalmologists in the US identify as an underrepresented minority.

When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.

Medicare’s 2023 fee schedule includes cuts in reimbursement, which some groups say could lead to reduced access to care to patients who need it most.

OVDs that are currently used in cataract surgery fit into different classes including higher viscosity cohesives, lower viscosity dispersives, viscoadaptives and higher viscosity dispersives.

Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.